211 related articles for article (PubMed ID: 27494842)
1. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Initial testing of dasatinib by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
6. Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Wang T; Cheng C; Peng L; Gao M; Xi M; Rousseaux S; Khochbin S; Wang J; Mi J
J Cell Mol Med; 2018 Mar; 22(3):1614-1626. PubMed ID: 29266867
[TBL] [Abstract][Full Text] [Related]
7. Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Ding YY; Kim H; Madden K; Loftus JP; Chen GM; Allen DH; Zhang R; Xu J; Chen CH; Hu Y; Tasian SK; Tan K
Clin Cancer Res; 2021 Sep; 27(18):5109-5122. PubMed ID: 34210682
[TBL] [Abstract][Full Text] [Related]
8. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
[No Abstract] [Full Text] [Related]
9. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Mustafa Ali MK; Sabha MM; Al-Rabi KH
Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
11. Novel Targeted Photosensitizer as an Immunomodulator for Highly Efficient Therapy of T-Cell Acute Lymphoblastic Leukemia.
Yuan G; Yao M; Lv H; Jia X; Chen J; Xue J
J Med Chem; 2020 Dec; 63(24):15655-15667. PubMed ID: 33300796
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
13. CBP Modulates Sensitivity to Dasatinib in Pre-BCR
Duque-Afonso J; Lin CH; Han K; Morgens DW; Jeng EE; Weng Z; Jeong J; Wong SHK; Zhu L; Wei MC; Chae HD; Schrappe M; Cario G; Duyster J; Xiao X; Sakamoto KM; Bassik MC; Cleary ML
Cancer Res; 2018 Nov; 78(22):6497-6508. PubMed ID: 30262461
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
16. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
18. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
